CTFA/CHPA Urge More Flexibility in Gingivitis Draft Guidance
This article was originally published in The Tan Sheet
Executive Summary
FDA's draft guidance for antigingivitis drug development and evaluation should encourage the creation of new indices that provide "meaningful and clinically relevant measures" of gingivitis, according to industry trade groups